Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Shuttle Pharmaceuticals Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Shuttle Pharmaceuticals Holdings şirketinin toplam hissedar öz sermayesi $801.4K ve toplam borcu $826.2K olup, bu da borç-öz sermaye oranını 103.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $2.8M ve $2.0M dir.

Anahtar bilgiler

103.1%

Borç/özkaynak oranı

US$826.24k

Borç

Faiz karşılama oranı	n/a
Nakit	US$2.34m
Eşitlik	US$801.43k
Toplam yükümlülükler	US$2.01m
Toplam varlıklar	US$2.81m

Son finansal sağlık güncellemeleri

Recent updates

Shuttle Pharma awarded new patents for its radiation sensitizing technology platform

Sep 15

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SHPH 'nin kısa vadeli varlıkları ( $2.5M ) kısa vadeli yükümlülüklerini ( $1.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: SHPH şirketinin kısa vadeli varlıkları ( $2.5M ) uzun vadeli yükümlülüklerini ( $626.9K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SHPH şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: SHPH şirketinin 5 yıl önce negatif özkaynağı vardı, ancak şu anda pozitif ve dolayısıyla iyileşme kaydetti.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: SHPH son raporlanan serbest nakit akışına göre 5 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: SHPH serbest nakit akışı tahminlerine göre 5 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Shuttle Pharmaceuticals Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Shuttle Pharmaceuticals Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement

Shuttle Pharmaceuticals Provides Regains Compliance with Nasdaq Listing Rule 5250(c)

Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Shuttle Pharmaceuticals Holdings, Inc. announced delayed 10-Q filing

Shuttle Pharmaceuticals Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Recent updates

Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering.

Shuttle Pharmaceuticals Holdings, Inc. Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement

Shuttle Pharmaceuticals Provides Regains Compliance with Nasdaq Listing Rule 5250(c)

Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals Holdings, Inc. announced delayed 10-Q filing

Shuttle Pharmaceuticals Holdings, Inc. Announces Publication of A Manuscript Reporting on the Ability of One of the Company’s HDAC Inhibitor Pre-Clinical Assets, SP-1-303

Shuttle Pharmaceuticals Holdings, Inc. Announces Chief Financial Officer Changes

Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Jul 31, 2024

New major risk - Financial position

New major risk - Financial position

New minor risk - Share price stability

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals Holdings, Inc. Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

New minor risk - Share price stability

Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Dec 18, 2023

Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Dec 18, 2023

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Shuttle Pharmaceuticals Holdings, Inc. Expands Patent Coverage on HDAC Inhibitor Platform

Shuttle Pharmaceuticals Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

New major risk - Financial position

Shuttle Pharmaceuticals Holdings Files Form 10-Q with the Securities and Exchange Commission and Regains Compliance with the Nasdaq Listing Rules

Shuttle Pharmaceuticals Holdings, Inc. announced delayed 10-Q filing

Shuttle Pharmaceuticals Holdings, Inc. announced that it has received $4 million in funding from Ayrton Capital LLC

Shuttle Pharmaceuticals Holdings, Inc. Announces the Publication of Manuscript Discussing Immune Responses Taking Place in Patients After Radiation Therapy for Cancer

Insufficient new directors

Shuttle Pharmaceuticals Holdings, Inc. Appoints Bette Jacobs to Its Board of Directors

Shuttle Pharmaceuticals Holdings, Inc. Receives New HDAC Inhibitor Patents for Cancer Treatment

Shuttle Pharma awarded new patents for its radiation sensitizing technology platform

Shuttle Pharmaceuticals Holdings, Inc. has completed an IPO in the amount of $9.96034 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin